Dyslipidemia Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Dyslipidemia Global Clinical Trials Review, H1, 2019" provides an overview of Dyslipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyslipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Merck & Co Inc

Pfizer Inc

AstraZeneca Plc

Kowa Co Ltd

GlaxoSmithKline Plc

Amgen Inc

Abbott Laboratories

Novartis AG

Chong Kun Dang Pharmaceutical Corp

AbbVie ...

Merck & Co Inc

Pfizer Inc

AstraZeneca Plc

Kowa Co Ltd

GlaxoSmithKline Plc

Amgen Inc

Abbott Laboratories

Novartis AG

Chong Kun Dang Pharmaceutical Corp

AbbVie Inc

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region ...

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials 21

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Dyslipidemia Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Dyslipidemia 38

Mar 11, 2019: Jeil releases P3 clinical trial results for anti-hypertension treatment 38

Clinical Trial Profile Snapshots 39

Appendix 1348

Abbreviations 1348

Definitions 1348

Research Methodology 1349

Secondary Research 1349

About GlobalData 1350

Contact Us 1350

Source 1351

List of Tables

Dyslipidemia Therapeutics, Global, Clinical Trials by Region, 2019* 8

Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dyslipidemia Therapeutics, Global, ...

Dyslipidemia Therapeutics, Global, Clinical Trials by Region, 2019* 8

Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Dyslipidemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12

Dyslipidemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Dyslipidemia Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Dyslipidemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15

Dyslipidemia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16

Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17

Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 22

Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Dyslipidemia Therapeutics, Global, Clinical Trials by Phase, 2019* 27

Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28

Dyslipidemia Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Dyslipidemia Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Dyslipidemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Dyslipidemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33

Dyslipidemia Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Dyslipidemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Dyslipidemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures

Dyslipidemia Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dyslipidemia Therapeutics, ...

Dyslipidemia Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Dyslipidemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12

Dyslipidemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Dyslipidemia Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14

Dyslipidemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15

Dyslipidemia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16

Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17

Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Dyslipidemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 22

Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Dyslipidemia Therapeutics, Global, Clinical Trials by Phase (%), 2019* 27

Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28

Dyslipidemia Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Dyslipidemia Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Dyslipidemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Dyslipidemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33

Dyslipidemia Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Dyslipidemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Dyslipidemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

GlobalData Methodology 1350

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports